Abstract
Neoadjuvant therapy (NAT), often referred to as primary therapy, is a wellestablished approach in the treatment of early breast cancer [1, 2]. Historically, NAT was initially used in women with locally advanced breast cancer. In this setting it represented the only chance for a patient with an otherwise inoperable cancer of the breast to obtain a tumor regression that made surgery feasible. These experiences in locally advanced tumors suggested that the primary breast cancers regressed frequently and, sometimes, became clinically undetectable during NAT. From locally advanced tumors, NAT was then studied in women with operable breast cancers, in whom it was speculated that anticancer treatment administered before surgery would offer a number of advantages compared to the traditional approach of surgery followed by adjuvant treatments. For example, in animal models, removal of the primary tumor was shown to have a permissive effect on distant micrometastases [3]; consequently, in the interval after breast surgery, micrometastases could grow to the extent that subsequent adjuvant treatments lost their efficacy. When potent chemotherapy agents such as the anthracyclines and, later, the taxanes became available, the rates of tumor regression observed in breast tumors were so impressive that NAT became synonymous with neoadjuvant chemotherapy (NAC).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kaufmann M, von MG, Smith R et al (2003) International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 21:2600–2608
Kaufmann M, Hortobagyi GN, Goldhirsch A et al (2006) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 24:1940–1949
Fisher B, Saffer E, Rudock C et al (1989) Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice. Cancer Res 49:2002–2004
Fisher B, Brown A, Mamounas E et al (1997) Effect of preoperative chemotherapy on localregional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483–2493
Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97:188–194
Berruti A, Brizzi MP, Generali D et al (2008) Presurgical systemic treatment of nonmetastatic breast cancer: facts and open questions. Oncologist 13:1137–1148
Prati R, Minami CA, Gornbein JA et al (2009) Accuracy of clinical evaluation of locally advanced breast cancer in patients receiving neoadjuvant chemotherapy. Cancer 115:1194–1202
Mann RM, Kuhl CK, Kinkel K, Boetes C (2008) Breast MRI: guidelines from the European Society of Breast Imaging. Eur Radiol 18:1307–1318
Tardivon AA, Ollivier L, El Khoury C, Thibault F (2006) Monitoring therapeutic efficacy in breast carcinomas. Eur Radiol 16:2549–2558
Sardanelli F, Boetes C, Borisch B et al (2010) Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer 46:1296–1316
Buchholz TA, Lehman CD, Harris JR et al (2008) Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. J Clin Oncol 26:791–797
Vinnicombe SJ, MacVicar AD, Guy RL et al (1996) Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. Radiology 198:333–340
Moskovic EC, Mansi JL, King DM et al (1993) Mammography in the assessment of response to medical treatment of large primary breast cancer. Clin Radiol 47:339–344
Huber S, Wagner M, Zuna I et al (2000) Locally advanced breast carcinoma: evaluation of mammography in the prediction of residual disease after induction chemotherapy. Anticancer Res 20:553–558
Helvie MA, Joynt LK, Cody RL et al (1996) Locally advanced breast carcinoma: accuracy of mammography vs clinical examination in the prediction of residual disease after chemotherapy. Radiology 198: 327–332
Croshaw R, Shapiro-Wright H, Svensson E et al (2011) Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients. Ann Surg Oncol 18:3160–3163. Epub Sep 27, 2011
Balu-Maestro C, Chapellier C, Bleuse A et al (2002) Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits in MRI. Breast Cancer Res Treat 72:145–152
Schott ZF, Roubidoux MA, Helvie MA et al (2002) Clinical and radiological assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat 92:231–238
Roubidoux MA, Le Carpentier GL, Fowles JB et al (2005) Sonographic evaluation of earlystage breast cancers that undergo neoadjuvant chemotherapy. J Ultrasound Med 24:885–895
Rieber A, Brambs HJ, Gabelmann A et al (2002) Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol 7:1711–1719
Yuan Y, Chen XS, Liu SY, Shen KW (2010) Accuracy of MRI in prediction of pathologic complete remission in breast cancer after preoperative therapy: a meta-analysis. AJR 195(1):260–268
Montemurro F, Martincich L, De Rosa G et al (2005) Dynamic contrast-enhanced MRI and sonography in patients receiving primary chemotherapy for breast cancer. Eur Radiol 15:1224–1233
Thibault F, Nos C, Meunier M et al (2004) MRI for surgical planning in patients with breast cancer who undergo preoperative chemotherapy. Am J Roentgenol 183:1159–1168
Wasser K, Klein SK, Fink C et al (2003) Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution. Eur Radiol 13:80–87
Loo CE, Straver ME, Rodenhuis S et al (2011) Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol 29:660–666
Padhani AR, Liu G, Koh DM et al (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11:102–125
Woodhams R, Kakita S, Hata H et al (2010) Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging-comparison with contrastenhanced MR imaging and pathologic findings. Radiology 254:357–366
Partridge SC, Gibbs JE, Lu Y et al (2005) MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol 184:1774–1781
Martincich L, Montemurro F, De Rosa G et al (2004) Monitoring response to primary chemotherapy in breast cancer using dynamic contrast enhanced magnetic resonance imaging. Breast Cancer Res Treat 83:67–76
Cheung YC, Chen SC, Su MY et al (2003) Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI. Breast Cancer Res Treat 78:51–58
El Khoury C, Servois V, Thibault F et al (2005) MR quantification of the washout changes in breast tumors under preoperative chemotherapy: feasibility and preliminary results. Am J Roentgenol 184:1499–1504
Leach MO, Brindle KM, Evelhoch JL et al (2003) Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Br J Radiol 76 Spec No 1:S87–S91
Padhani AR, Hayes C, Assersohn L et al (2006) Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology 239:361–374
Ah-See ML, Makris A, Taylor NJ et al (2008) Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 14:6580–6589
Sardanelli F, Fausto A, Podo F (2008) MR spectroscopy of the breast. Radiol Med 113:56–64
Jagannathan NR, Kumar M, Seenu V et al (2001) Evaluation of total choline from in vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer 84:1016–1022
Tozaki M, Sakamoto M, Oyama Y et al (2010) Predicting pathological response to neoadjuvant chemotherapy in breast cancer with quantitative 1H MR spectroscopy using the external standard method. J Magn Reson Imaging 31:895–902
Meisamy S, Bolan PJ, Baker EH et al (2004) Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1) HMR spectroscopy-a pilot study at 4 T. Radiology 233:424–431
Hamstra DA, Rehemtulla A, Ross BD (2007) Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 25:4104–4109
Park SH, Moon WK, Cho N et al (2010) Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Radiology 257:56–63
Pickles MD, Gibbs P, Lowry M, Turnbull LW (2006) Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 24:843–847
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Italia
About this chapter
Cite this chapter
Martincich, L., Bertotto, I., Montemurro, F. (2012). Neoadjuvant Therapy in Breast Cancer. In: Aglietta, M., Regge, D. (eds) Imaging Tumor Response to Therapy. Springer, Milano. https://doi.org/10.1007/978-88-470-2613-1_6
Download citation
DOI: https://doi.org/10.1007/978-88-470-2613-1_6
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-2612-4
Online ISBN: 978-88-470-2613-1
eBook Packages: MedicineMedicine (R0)